
Oncopeptides AB
STO:ONCO

Intrinsic Value
The intrinsic value of one
ONCO
stock under the Base Case scenario is
2.44
SEK.
Compared to the current market price of 1.48 SEK,
Oncopeptides AB
is
Undervalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Oncopeptides AB
Fundamental Analysis


Revenue & Expenses Breakdown
Oncopeptides AB
Balance Sheet Decomposition
Oncopeptides AB
Current Assets | 148.6m |
Cash & Short-Term Investments | 107.2m |
Receivables | 35.4m |
Other Current Assets | 6m |
Non-Current Assets | 24.8m |
Other Non-Current Assets | 24.8m |
Free Cash Flow Analysis
Oncopeptides AB
SEK | |
Free Cash Flow | SEK |
Earnings Waterfall
Oncopeptides AB
Revenue
|
39.8m
SEK
|
Cost of Revenue
|
-2.3m
SEK
|
Gross Profit
|
37.6m
SEK
|
Operating Expenses
|
-315.2m
SEK
|
Operating Income
|
-277.7m
SEK
|
Other Expenses
|
99k
SEK
|
Net Income
|
-277.6m
SEK
|
ONCO Profitability Score
Profitability Due Diligence
Oncopeptides AB's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Score
Oncopeptides AB's profitability score is 46/100. The higher the profitability score, the more profitable the company is.
ONCO Solvency Score
Solvency Due Diligence
Oncopeptides AB's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Score
Oncopeptides AB's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ONCO Price Targets Summary
Oncopeptides AB
According to Wall Street analysts, the average 1-year price target for
ONCO
is 5.79 SEK
with a low forecast of 1.72 SEK and a high forecast of 14.7 SEK.
Dividends
Current shareholder yield for ONCO is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ONCO
stock under the Base Case scenario is
2.44
SEK.
Compared to the current market price of 1.48 SEK,
Oncopeptides AB
is
Undervalued by 39%.